IS5200A - Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum - Google Patents

Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum

Info

Publication number
IS5200A
IS5200A IS5200A IS5200A IS5200A IS 5200 A IS5200 A IS 5200A IS 5200 A IS5200 A IS 5200A IS 5200 A IS5200 A IS 5200A IS 5200 A IS5200 A IS 5200A
Authority
IS
Iceland
Prior art keywords
cgmppde5
pyrazolopyrimidinone
treatment
cyclic guanosine
sexual disorders
Prior art date
Application number
IS5200A
Other languages
English (en)
Inventor
Edward Bunnage Mark
Paul Mathias John
Derek Albert Street Stephen
Wood Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9708406.5A external-priority patent/GB9708406D0/en
Priority claimed from GB9715380A external-priority patent/GB9715380D0/en
Priority claimed from GBGB9722954.6A external-priority patent/GB9722954D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5200A publication Critical patent/IS5200A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5200A 1997-04-25 1999-09-28 Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum IS5200A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9708406.5A GB9708406D0 (en) 1997-04-25 1997-04-25 Therapeutic agents
GB9715380A GB9715380D0 (en) 1997-07-22 1997-07-22 Therapeutic agents
GBGB9722954.6A GB9722954D0 (en) 1997-10-30 1997-10-30 Therapeutic agents
PCT/EP1998/002257 WO1998049166A1 (en) 1997-04-25 1998-04-10 PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
IS5200A true IS5200A (is) 1999-09-28

Family

ID=27268823

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5200A IS5200A (is) 1997-04-25 1999-09-28 Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum

Country Status (31)

Country Link
US (2) US6723719B1 (is)
EP (1) EP0977756A1 (is)
JP (2) JP3563078B2 (is)
KR (2) KR100390612B1 (is)
CN (2) CN1281588C (is)
AP (1) AP1002A (is)
AR (1) AR015595A1 (is)
AU (1) AU730670B2 (is)
BG (1) BG103828A (is)
BR (1) BR9810233A (is)
CA (1) CA2288910C (is)
CO (1) CO4940472A1 (is)
CZ (1) CZ299633B6 (is)
DZ (1) DZ2465A1 (is)
EA (2) EA002057B1 (is)
HR (1) HRP980222B1 (is)
ID (1) ID22834A (is)
IL (5) IL132276A0 (is)
IS (1) IS5200A (is)
MA (1) MA24529A1 (is)
NO (1) NO314585B1 (is)
NZ (1) NZ338075A (is)
OA (1) OA11168A (is)
PA (1) PA8450401A1 (is)
PE (1) PE68699A1 (is)
PL (1) PL336586A1 (is)
RS (1) RS50118B (is)
SK (1) SK285991B6 (is)
TN (1) TNSN98053A1 (is)
TR (1) TR199902646T2 (is)
WO (1) WO1998049166A1 (is)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
BR9810233A (pt) 1997-04-25 2000-10-17 Pfizer Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
EA200000969A1 (ru) * 1998-04-20 2001-06-25 Пфайзер Инк. ИНГИБИТОРЫ цГМБ ФДЭ5 НА ОСНОВЕ ПИРАЗОЛПИРИМИДИНОНА ДЛЯ ЛЕЧЕНИЯ ПОЛОВЫХ ДИСФУНКЦИЙ
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
RU2220145C2 (ru) * 1998-11-11 2003-12-27 Донг А Фарм. Ко., Лтд. Производные пиразолопиримидинона для лечения импотенции и способ их получения
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
NO20002097L (no) * 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US6613768B1 (en) * 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6242444B1 (en) 1999-06-04 2001-06-05 The Jordanian Pharmaceutical Manufacturing And Medical Equipment Co., Ltd. Compounds and pharmaceutical compositions containing the same
ES2183500T3 (es) * 1999-06-04 2003-03-16 Jordanian Pharmaceutical Mfg A Nuevos compuestos y composiciones farmaceuticas que los contienen.
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
NZ517324A (en) 1999-10-11 2003-09-26 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
US6350751B1 (en) 1999-10-11 2002-02-26 Pfizer Inc. Therapeutic agents
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
ES2231311T3 (es) 1999-12-24 2005-05-16 Bayer Healthcare Ag Triazolotriazinonas y su uso.
CN1434825A (zh) 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
AU2000254308A1 (en) * 2000-05-17 2001-11-26 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
KR100377782B1 (ko) * 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
AU2001276607A1 (en) * 2000-08-11 2002-02-25 Pfizer Inc. Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
WO2002016364A1 (en) * 2000-08-23 2002-02-28 Lg Life Sciences Ltd. Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
MXPA04004370A (es) 2001-11-09 2004-08-11 Schering Corp Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
DK1348707T3 (da) * 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
ATE433978T1 (de) 2003-04-29 2009-07-15 Pfizer Ltd 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
PL1633364T3 (pl) * 2004-01-05 2008-07-31 Teva Pharma Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu
US7449462B2 (en) 2004-01-22 2008-11-11 Pfizer, Inc. Triazole derivatives which inhibit vasopressin antagonistic activity
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
EP2522670A1 (en) * 2004-04-07 2012-11-14 Takeda Pharmaceutical Company Limited Heterocyclic CRF receptor antagonists
WO2005097799A1 (en) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US7618972B2 (en) 2005-03-21 2009-11-17 Pfizer Inc Substituted triazole derivatives as oxytocin antagonists
PT2366393E (pt) 2005-04-19 2013-10-04 Takeda Gmbh Roflumilaste para o tratamento da hipertensão pulmonar
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
ATE493413T1 (de) 2005-05-12 2011-01-15 Pfizer Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US20080318982A1 (en) * 2005-12-20 2008-12-25 Pfizer, Inc. Pharmaceutical Combination for the Treatment of Luts
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
BR122014017503B8 (pt) 2010-11-03 2022-10-11 Dow Agrosciences Llc Moléculas pesticidas
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
WO2013036081A2 (en) * 2011-09-09 2013-03-14 Sk Chemicals Co., Ltd. Composition for reducing skin wrinkles including pde5 inhibitor
PH12014500930A1 (en) 2011-10-26 2014-06-09 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US8901153B2 (en) 2012-04-27 2014-12-02 Dow Agrosciences, Llc. Pesticidal compositions and processes related thereto
EP2903619B1 (en) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
EP3022205B1 (en) 2013-07-17 2020-02-05 The Trustees of Columbia University in the City of New York Novel phosphodiesterase inhibitors and uses thereof
US9102655B2 (en) 2013-10-17 2015-08-11 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3057429A4 (en) 2013-10-17 2017-08-09 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
CN105636446B (zh) 2013-10-17 2018-07-13 美国陶氏益农公司 制备杀虫化合物的方法
WO2015058028A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004948A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de un compuesto pesticida.
JP2016535010A (ja) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
CN105636444B (zh) 2013-10-17 2018-04-27 美国陶氏益农公司 制备杀虫化合物的方法
MX2016005316A (es) 2013-10-22 2017-03-01 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
WO2015061175A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
TW201519786A (zh) 2013-10-22 2015-06-01 陶氏農業科學公司 殺蟲組成物及相關方法（一）
NZ719754A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2927195A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2926647A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
CN105792651A (zh) 2013-10-22 2016-07-20 美国陶氏益农公司 杀虫组合物和与其相关的方法
US9144241B2 (en) 2013-10-22 2015-09-29 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
WO2015061142A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP6509209B2 (ja) 2013-10-22 2019-05-08 ダウ アグロサイエンシィズ エルエルシー 農薬組成物および関連する方法
CA2925898A1 (en) 2013-10-22 2015-04-30 Luis E. Gomez Synergistic pesticidal compositions and related methods
MX2016005330A (es) 2013-10-22 2016-08-03 Dow Agrosciences Llc Composiciones pesticidas y metodos relacionados.
KR20160074635A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
US9801376B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2656889C2 (ru) 2013-10-22 2018-06-07 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и соответствующие способы
CA2927214A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2016119359A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и связанные с ними способы
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
AR098110A1 (es) 2014-07-31 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
AR098108A1 (es) 2014-07-31 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
KR20170038785A (ko) 2014-07-31 2017-04-07 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
KR20170042714A (ko) 2014-08-19 2017-04-19 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP2017528469A (ja) 2014-09-12 2017-09-28 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
EP3725789B1 (en) * 2014-09-17 2022-03-09 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
AU2017322427B2 (en) 2016-09-09 2021-12-23 Incyte Corporation Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer
JP2020503336A (ja) 2016-12-29 2020-01-30 ダウ アグロサイエンシィズ エルエルシー 殺有害生物化合物の調製方法
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
WO2019164846A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
TW202028207A (zh) 2018-09-25 2020-08-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
BR112021009958A2 (pt) * 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
MX2021012409A (es) 2019-04-10 2021-11-12 Mayo Found Medical Education & Res Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
PH12022550271A1 (en) 2019-08-06 2023-06-26 Incyte Corp Solid forms of an hpk1 inhibitor
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法
CN115785101B (zh) * 2022-11-23 2023-10-13 西安市食品药品检验所 一种含有苯基哌嗪结构的那非类化合物及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
DE3420985A1 (de) 1983-10-15 1985-04-25 Bayer Ag, 5090 Leverkusen Substituierte 5-acylamino-1-phenylpyrazole
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
KR19980702892A (ko) 1995-03-10 1998-08-05 보먼 메리 피 6-아릴 피라졸로[3,4-디]피리미딘-4-온 및 그의 조성물 및 그의사용 방법
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
BR9810233A (pt) 1997-04-25 2000-10-17 Pfizer Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
EA200000969A1 (ru) 1998-04-20 2001-06-25 Пфайзер Инк. ИНГИБИТОРЫ цГМБ ФДЭ5 НА ОСНОВЕ ПИРАЗОЛПИРИМИДИНОНА ДЛЯ ЛЕЧЕНИЯ ПОЛОВЫХ ДИСФУНКЦИЙ
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
AP9801228A0 (en) 1998-06-30
IL157645A (en) 2007-03-08
NO995211D0 (no) 1999-10-25
YU52499A (is) 2002-08-12
CZ376799A3 (cs) 2000-04-12
PL336586A1 (en) 2000-07-03
JP2004196820A (ja) 2004-07-15
OA11168A (en) 2003-04-28
NO995211L (no) 1999-10-25
CZ299633B6 (cs) 2008-09-24
AU7644598A (en) 1998-11-24
MA24529A1 (fr) 1998-12-31
NO314585B1 (no) 2003-04-14
AR015595A1 (es) 2001-05-16
ID22834A (id) 1999-12-09
KR100390612B1 (ko) 2003-07-07
EA004315B1 (ru) 2004-02-26
IL132276A0 (en) 2001-03-19
IL132276A (en) 2006-06-11
CA2288910A1 (en) 1998-11-05
CA2288910C (en) 2003-06-24
BG103828A (en) 2000-06-30
JP3563078B2 (ja) 2004-09-08
EP0977756A1 (en) 2000-02-09
CO4940472A1 (es) 2000-07-24
TNSN98053A1 (fr) 2005-03-15
IL157647A (en) 2007-05-15
HK1027808A1 (en) 2001-01-23
KR100441229B1 (ko) 2004-07-22
US20040180944A1 (en) 2004-09-16
US6916927B2 (en) 2005-07-12
DZ2465A1 (fr) 2003-01-18
JP2000510485A (ja) 2000-08-15
JP4036836B2 (ja) 2008-01-23
AU730670B2 (en) 2001-03-08
HRP980222B1 (en) 2003-12-31
EA200100504A1 (ru) 2002-02-28
WO1998049166A1 (en) 1998-11-05
CN1253561A (zh) 2000-05-17
KR20010020285A (ko) 2001-03-15
CN1188415C (zh) 2005-02-09
CN1281588C (zh) 2006-10-25
CN1626516A (zh) 2005-06-15
PE68699A1 (es) 1999-07-10
EA002057B1 (ru) 2001-12-24
NZ338075A (en) 2000-10-27
PA8450401A1 (es) 2000-05-24
EA199900866A1 (ru) 2000-04-24
RS50118B (sr) 2009-03-25
SK144699A3 (en) 2001-03-12
SK285991B6 (sk) 2008-01-07
IL157646A (en) 2006-12-10
BR9810233A (pt) 2000-10-17
HRP980222A2 (en) 1999-02-28
TR199902646T2 (xx) 2000-05-22
AP1002A (en) 2001-08-14
US6723719B1 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
IS5200A (is) Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
IT1302060B1 (it) Dispositivo per il trattamento di moxa del tipo shiatsu.
DK0751129T6 (da) Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
IS5085A (is) Nefholssamsetningar til meðhöndlunar á kynferðistruflunum
DK0861081T3 (da) Anvendelse af epinastin til behandling af smerter
DE60208794D1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
EP1569652A4 (en) NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS
ZA200006312B (en) Antibodies to CD23, derivatives thereof, and their therapeutic uses.
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
EP1292279A4 (en) USE OF GLATIRAMER ACETATE (COPOLYMER 1) FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
DK1041985T3 (da) Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
ZA9811715B (en) Aqueous insecticidal pour-on treatment.
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
IT1303677B1 (it) Dispositivo per il trattamento termico di pezzi.
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
ITRM950180V0 (it) Allestimenti per lo svolgimento del gioco "wormhole action match".
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
ZA991783B (en) Therapeutic treatment for autoimmune diseases.
ZA200103156B (en) Methods of downmodulating the immune response to therapeutic proteins.